Tag : Shionogi

Latest News

Shionogi Launches FETCROJA® (cefiderocol) in the United Kingdom for the Treatment of Infections Due to Aerobic Gram-Negative Bacteria in Adults With Limited Treatment Options

Newsemia
OSAKA, Japan & AMSTERDAM–(BUSINESS WIRE)–Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter “Shionogi”), today announced the launch of a new antibiotic, cefiderocol,...
Latest News

Shionogi Announces Launch of Mulpleo® (lusutrombopag) in the UK, for the Treatment of Severe Thrombocytopenia in Adult Patients With Chronic Liver Disease Undergoing Invasive Procedures

Newsemia
OSAKA, Japan & AMSTERDAM–(BUSINESS WIRE)–Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter “Shionogi”), today announce the launch of Mulpleo® (lusutrombopag) in the...
Latest News

Shionogi riferisce risultati positivi di uno studio di fase III su cefiderocol negli adulti con polmonite nosocomiale causata da agenti patogeni Gram-negativi

Newsemia
AMSTERDAM, Paesi Bassi–(BUSINESS WIRE)–Shionogi & Co., Ltd. (di seguito “Shionogi”) ha reso noti i risultati di APEKS-NP, uno studio clinico internazionale di fase III randomizzato...
Latest News

Shionogi et Ferrer concluent un contrat pour la promotion en Espagne du ▼ RIZMOIC® (naldemedine), un agent thérapeutique contre la constipation induite par les opioïdes

Newsemia
AMSTERDAM & BARCELONE, Espagne–(BUSINESS WIRE)–SHIONOGI B.V., la filiale européenne de SHIONOGI & Co, Ltd. (Siège social : Osaka, Japon ; Président & DG : Isao...
Latest News

Shionogi Announces Data Demonstrating Potent in Vitro Activity of Cefiderocol against the Most Critical Priority Gram-Negative Bacterial Pathogens

Newsemia
OSAKA, Japan & AMSTERDAM–(BUSINESS WIRE)–Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.) and Shionogi B.V. the European subsidiary of...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy